文献速递淋巴瘤

开发新型神经酰胺类似物并鉴定受鞘脂代谢调控的抗病毒相关淋巴瘤新基因

Developing new ceramide analogs and identifying novel sphingolipid-controlled genes against a virus-associated lymphoma.
PubMed 文献 · Blood · 2020-01-01

原发性渗出性淋巴瘤(PEL)侵袭性强、预后差且缺乏特异性治疗。本研究通过筛选新合成的神经酰胺类似物,鉴定出具有抗PEL活性的化合物,其可诱导PEL细胞凋亡、周期阻滞并增加细胞内神经酰胺,在体内显著抑制肿瘤进展且未见明显毒性,同时上调病毒裂解基因表达。比较转录组分析揭示其作用机制,并鉴定出受鞘脂代谢调控、PEL存活所需的AURKA和CDCA3等新基因。

要点

  • 新型神经酰胺类似物可诱导PEL细胞凋亡、周期阻滞并增加细胞内神经酰胺。
  • 化合物在体内显著抑制肿瘤进展且未见明显毒性,并上调病毒裂解基因表达。
  • 鉴定出受鞘脂代谢调控且PEL存活所需的AURKA和CDCA3等新基因。

核心结论

  • 数据为开发基于鞘脂代谢的疗法对抗该病毒相关恶性肿瘤提供了框架。

研究设计与样本

  • 研究筛选了一系列新合成的神经酰胺类似物,并进行了体外和体内功能验证及比较转录组分析。

主要发现

  • 化合物诱导显著的PEL细胞凋亡、细胞周期阻滞,并通过调节神经酰胺合成或代谢酶增加细胞内神经酰胺产生。
  • 化合物在体内显著抑制肿瘤进展且未见明显毒性。
  • 化合物增加PEL细胞中病毒裂解基因表达。
  • 比较转录组分析鉴定出受鞘脂代谢调控的新细胞基因,包括AURKA和CDCA3,且这些基因经功能验证为PEL存活所需。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary effusion lymphoma (PEL) is an aggressive malignancy with poor prognosis even under chemotherapy. Kaposi sarcoma-associated herpesvirus (KSHV), one of the human oncogenic viruses, is the principal causative agent. Currently, there is no specific treatment for PEL; therefore, developing new therapies is of great importance. Sphingolipid metabolism plays an important role in determining the fate of tumor cells. Our previous studies have demonstrated that there is a correlation between sphingolipid metabolism and KSHV+ tumor cell survival. To further develop sphingolipid metabolism-targeted therapy, after screening a series of newly synthesized ceramide analogs, here, we have identified compounds with effective anti-PEL activity. These compounds induce significant PEL apoptosis, cell-cycle arrest, and intracellular ceramide production through regulation of ceramide synthesizing or ceramide metabolizing enzymes and dramatically suppress tumor progression without visible toxicity in vivo. These new compounds also increase viral lytic gene expression in PEL cells. Our comparative transcriptomic analysis revealed their mechanisms of action for inducing PEL cell death and identified a subset of novel cellular genes, including AURKA and CDCA3, controlled by sphingolipid metabolism, and required for PEL survival with functional validation. These data provide the framework for the development of promising sphingolipid-based therapies against this virus-associated malignancy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Chen J, Goyal N, Dai L, et al. Developing new ceramide analogs and identifying novel sphingolipid-controlled genes against a virus-associated lymphoma. Blood. 2020. PMID: 32518949. doi:10.1182/blood.2020005569

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。